Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allarity Therapeutics, Inc. - Common stock (NQ: ALLR )

0.1494 -0.0186 (-11.07%)
Streaming Delayed Price Updated: 10:15 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Allarity Therapeutics, Inc. - Common stock

< Previous 1 2 Next >
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Inc. (NASDAQ: ALLR) Near the Top of Equities by Percentage Gain on 4/12
Via Investor Brand Network
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics to Present at Biomarkers 2024
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics to Present at Biomarkers Europe 2023
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology
Via ACCESSWIRE
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Inc. (NASDAQ: ALLR) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Allarity Therapeutics (NASDAQ: ALLR) Reports Early Success in Phase 2 Trial for Breast Cancer Drug IXEMPRA®
Allarity Therapeutics (NASDAQ: ALLR), a clinical-stage pharmaceutical company, recently announced preliminary results from its Phase 2 clinical trial assessing the 
Via Spotlight Growth
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.